Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells

Status Completed

Clinical Trial Summary

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.

Clinical Trial Description

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with Lung Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the Lung cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the Lung cancer patient using a similar protocol as investigators reported .

Aim 1: To demonstrate, in vitro, the relative cellular anti-Lung cancer CSC immunity induced by Lung cancer CSC-DC primed cytotoxic T cells.

Aim 2: To determine, in vitro, specific binding and lysis of Lung cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with Lung cancer CSC-DC. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02084823
Study type	Interventional
Source	Fuda Cancer Hospital, Guangzhou
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 2014
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01860898` - A Phase I Study of iPS Cell Generation From Patients With COPD	N/A
Recruiting	`NCT04892342` - Study of ESG401 in Adults With Solid Tumors	Phase 1/Phase 2
Completed	`NCT05011890` - Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®	N/A
Active, not recruiting	`NCT00935571` - Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia	N/A
Completed	`NCT02115958` - The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine	Phase 1/Phase 2
Terminated	`NCT02673021` - MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)	N/A
Terminated	`NCT03603652` - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung	N/A
Not yet recruiting	`NCT01131429` - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations	Phase 2
Completed	`NCT00042679` - A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.	Phase 2
Not yet recruiting	`NCT05857995` - Precision Lung Cancer Survivorship Care Intervention	N/A
Withdrawn	`NCT03713099` - NEUWAVE Flexible Probe Study #2	N/A
Completed	`NCT00284141` - Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma	Phase 2
Recruiting	`NCT04699188` - Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/Phase 2
Terminated	`NCT00290017` - Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy	Phase 3
Completed	`NCT02410603` - Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
Recruiting	`NCT02549638` - Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Completed	`NCT02370303` - A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System